Achaogen, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 15 rows in 2015. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2015-12-28: Reporting owner Sarpangal Zeryn; Form 3; Security Stock Option (Right to Buy); Transaction Holding.
- 2015-12-28: Reporting owner Sarpangal Zeryn; Form 3; Security Stock Option (Right to Buy); Transaction Holding.
- 2015-11-04: Reporting owner Fischbach Michael; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2015-10-01: Reporting owner Wise Blake; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2015-12-28 holding as of filing | Sarpangal Zeryn Officer (VP, HR and Corporate Affairs) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $14.89 exercise price | 2015-12-28 | ||
| 2015-12-28 holding as of filing | Sarpangal Zeryn Officer (VP, HR and Corporate Affairs) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $6.99 exercise price | 2015-12-28 | ||
| 2015-11-04 | Fischbach Michael Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $5.73 exercise price | 2015-11-06 | |
| 2015-10-01 | Wise Blake Officer (Chief Operating Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +162,500 162,500 owned after | $5.86 exercise price | 2015-10-02 | |
| 2015-06-10 | STEA GREGORY Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $5.53 exercise price | 2015-06-11 | |
| 2015-06-10 | WALSH CHRISTOPHER T PHD Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $5.53 exercise price | 2015-06-11 | |
| 2015-06-10 | Smither John W Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $5.53 exercise price | 2015-06-11 | |
| 2015-06-10 | ROBERTS BRYAN E Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $5.53 exercise price | 2015-06-11 | |
| 2015-06-10 | DOYLE JOHN C Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +10,000 10,000 owned after | $5.53 exercise price | 2015-06-11 | |
| 2015-03-11 | Colowick Alan Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $10.44 exercise price | 2015-03-13 | |
| 2015-03-11 | Lieginger Kent Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $10.44 exercise price | 2015-03-13 | |
| 2015-03-11 | Hillan Kenneth J. Director, Officer (Chief Executive Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +111,700 111,700 owned after | $10.44 exercise price | 2015-03-13 | |
| 2015-03-11 | BERTOCCI DEREK A Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +37,250 37,250 owned after | $10.44 exercise price | 2015-03-13 | |
| 2015-02-05 | Murray Christine Officer (VP, Regulatory Affairs) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +21,500 21,500 owned after | $11.78 exercise price | 2015-02-09 | |
| 2015-02-05 | Friedland Ian Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +51,500 51,500 owned after | $11.78 exercise price | 2015-02-09 |